Search Results for "vaccine, hepatitis A"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vaccine, hepatitis A. Results 31 to 40 of 53 total matches.
See also: Avaxim, Havrix, Twinrix, Vaqta

Ozanimod (Zeposia) for Ulcerative Colitis

   
The Medical Letter on Drugs and Therapeutics • Sep 20, 2021  (Issue 1633)
the efficacy of vaccines. Liveattenuated vaccines should not be administered for at least 1 month before ...
The oral sphingosine 1-phosphate (S1P) receptor modulator ozanimod (Zeposia – Bristol Myers Squibb) has been approved by the FDA for treatment of adults with moderately to severely active ulcerative colitis. It is the first S1P receptor modulator to be approved for treatment of ulcerative colitis. Ozanimod was approved in March 2020 for use in adults with relapsing forms of multiple sclerosis.
Med Lett Drugs Ther. 2021 Sep 20;63(1633):147-51 |  Show IntroductionHide Introduction

Three Drugs for Atopic Dermatitis (Adbry, Cibinqo, and Rinvoq)

   
The Medical Letter on Drugs and Therapeutics • Apr 03, 2023  (Issue 1673)
. Increases in lipid and hepatic enzyme levels can occur with use of upadacitinib. GI perforations ...
The subcutaneously injected interleukin-13 (IL-13) antagonist tralokinumab-ldrm (Adbry – Leo) and the oral Janus kinase (JAK) inhibitors abrocitinib (Cibinqo – Pfizer) and upadacitinib (Rinvoq – Abbvie) have been approved by the FDA for treatment of moderate to severe atopic dermatitis.
Med Lett Drugs Ther. 2023 Apr 3;65(1673):51-5   doi:10.58347/tml.2023.1673b |  Show IntroductionHide Introduction

Ozanimod (Zeposia) for Multiple Sclerosis

   
The Medical Letter on Drugs and Therapeutics • Aug 24, 2020  (Issue 1605)
ozanimod with another QT interval-prolonging drug.15 Ozanimod may reduce the efficacy of vaccines ...
The FDA has approved ozanimod (Zeposia – Celgene), a sphingosine 1-phosphate (S1P) receptor modulator, for treatment of adults with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome (initial neurological episode), relapsing-remitting disease, and active secondary progressive MS (SPMS). It is the third oral S1P receptor modulator to be approved in the US for treatment of relapsing forms of MS; siponimod (Mayzent) is also indicated for use in adults, and fingolimod (Gilenya) is approved for use in patients ≥10 years old.
Med Lett Drugs Ther. 2020 Aug 24;62(1605):132-4 |  Show IntroductionHide Introduction

Drugs for COPD

   
The Medical Letter on Drugs and Therapeutics • Sep 02, 2024  (Issue 1710)
; pharmacotherapy can be helpful. ▶ Influenza and pneumococcal vaccines are recommended to decrease the incidence ...
The main goals of treatment of chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, prevent disease progression, and reduce mortality. GOLD (Global Initiative for Chronic Obstructive Lung Disease) guidelines for treatment of COPD were updated recently. Treatment of acute exacerbations is not discussed here. Drugs available for treatment of COPD are listed in Tables 1 and 3.
Med Lett Drugs Ther. 2024 Sep 2;66(1710):137-44   doi:10.58347/tml.2024.1710a |  Show IntroductionHide Introduction

Treatment of Common Respiratory Tract Infections

   
The Medical Letter on Drugs and Therapeutics • Apr 17, 2023  (Issue 1674)
. Dosage adjustments may be needed for renal or hepatic impairment. Doxycycline, clarithromycin ...
Most respiratory tract infections are caused by viruses. Bacterial respiratory tract infections are usually treated empirically with antibiotic therapy that targets the most probable causative pathogens. Recommended antibiotic regimens for outpatient treatment of some common respiratory tract infections are listed in Table 1 for adults and Table 2 for children.
Med Lett Drugs Ther. 2023 Apr 17;65(1674):57-62   doi:10.58347/tml.2023.1674a |  Show IntroductionHide Introduction

Budesonide Oral Suspension (Eohilia) for Eosinophilic Esophagitis

   
The Medical Letter on Drugs and Therapeutics • Jun 10, 2024  (Issue 1704)
years (estimated prevalence 40 cases per 100,000 persons).2 EoE is thought to be an abnormal immune ...
Eohilia (Takeda), an oral suspension formulation of the corticosteroid budesonide, has been approved by the FDA for treatment of eosinophilic esophagitis (EoE) in patients ≥11 years old. It is the first oral drug to be approved in the US for this indication. The subcutaneously injected interleukin (IL)-4 receptor antagonist dupilumab (Dupixent) is approved for treatment of EoE in patients ≥1 year old who weigh ≥15 kg.
Med Lett Drugs Ther. 2024 Jun 10;66(1704):93-5   doi:10.58347/tml.2024.1704c |  Show IntroductionHide Introduction

An EUA for Tocilizumab (Actemra) for COVID-19

   
The Medical Letter on Drugs and Therapeutics • Jul 26, 2021  (Issue 1629)
, including localized infections. Neutropenia, thrombocytopenia, serum hepatic transaminase elevations ...
The interleukin-6 (IL-6) receptor antagonist tocilizumab (Actemra – Genentech) has received an Emergency Use Authorization (EUA) from the FDA for IV treatment of COVID-19 in hospitalized patients ≥2 years old who are receiving a systemic corticosteroid and require supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). Tocilizumab has been approved by the FDA for various indications, including rheumatoid arthritis and juvenile idiopathic arthritis.
Med Lett Drugs Ther. 2021 Jul 26;63(1629):113-4 |  Show IntroductionHide Introduction

Expanded Table: Some Drugs for Inflammatory Bowel Disease (online only)

   
The Medical Letter on Drugs and Therapeutics • Jul 10, 2023  (Issue 1680)
and Listeria Reactivation of hepatitis B virus in patients who are chronic carriers Injection and infusion ...
View the Table: Some Drugs for Inflammatory Bowel Disease
Med Lett Drugs Ther. 2023 Jul 10;65(1680):e115-9   doi:10.58347/tml.2023.1680d |  Show IntroductionHide Introduction

Drugs for Plaque Psoriasis

   
The Medical Letter on Drugs and Therapeutics • Sep 30, 2024  (Issue 1712)
of skin cells, reducing expression of immune markers. Ultraviolet A (UVA) exposure can inactivate ...
Mild to moderate plaque psoriasis can be treated with topical drugs and phototherapy. Patients with moderate to severe disease generally require systemic therapy. Guidelines for the treatment of psoriasis with topical therapy, phototherapy, and systemic drugs have recently been published.
Med Lett Drugs Ther. 2024 Sep 30;66(1712):153-60   doi:10.58347/tml.2024.1712a |  Show IntroductionHide Introduction

Antibacterial Drugs for Community-Acquired Pneumonia

   
The Medical Letter on Drugs and Therapeutics • Jan 25, 2021  (Issue 1616)
common causative bacterial pathogens. In the US, pneumococcal vaccination has substantially reduced ...
Treatment of community-acquired pneumonia (CAP) is usually empiric, with selected antibiotic regimens directed against some of the most common causative pathogens. Recommended empiric regimens are listed in Table 2; recommended antibiotic dosages for treatment of CAP are listed in Tables 3 and 4. Joint guidelines for treatment of CAP by the American Thoracic Society and the Infectious Diseases Society of America (ATS/IDSA) were updated in 2019.
Med Lett Drugs Ther. 2021 Jan 25;63(1616):10-5 |  Show IntroductionHide Introduction